22. phytotherapy for carcinoma of prostate yip andrew
Dawdy_Ferman_Family_Conference_Room _2016
1. PROTEOMICS
Rapid Measurement of Lung
Cancer Biomarkers
Ambermarie Dawdy
August 01, 2016
Jin H. Park, Biochem J., 2012,448(Pt 3): 417-423
2. Why Should we Study Lung Cancer?
Rebecca L. Siegel, CA CANCER J CLIN 2016,66, 11-18
Estimated New Cases
Prostate 21%
Lung & Bronchus 14%
Colon & Rectum 8%
Urinary Bladder 7%
Melanoma 6%
Lymphoma 5%
Kidney & Renal 5%
Oral & Pharynx 4%
Leukemia 4%
Liver & Bile Duct 3%
Lung & Bronchus 27%
Prostate 8%
Colon & Rectum 8%
Pancreas 7%
Liver & Bile Duct 3%
Leukemia 4%
Esophagus 4%
Urinary Bladder 4%
Lymphoma 4%
Brain & Nervous 3%
Breast
Lung & Bronchus
Colon & Rectum
Uterine corpus
Thyroid
Lymphoma
Melanoma
Leukemia
Pancreas
Kidney & Renal
Lung & Bronchus
Breast
Colon & Rectum
Pancreas
Ovary
Uterine corpus
Leukemia
Liver & Bile Duct
Lymphoma
Brain & Nervous
Estimated Deaths
29%
13%
8%
7%
6%
4%
3%
3%
3%
3%
26%
14%
8%
7%
5%
4%
4%
3%
3%
2%
*17,369 Cases of estimated new cases in Florida and 11,960 estimated deaths from lung cancer
3. What are Biomarkers?
• Measurable substances in
organisms whose presence is
indicative of a biological
occurrence such as
disease/infection
• Tissue microarray is used to
remove sections of tumor
tissue and clinical biopsies
• Reduces the time it takes to
process tissue microarrays
from 3 hours a sample to 12
minutes a sample
Mascaux C, Clin Cancer Res, 2011,17, 7801
7. SUMMARY
● Lung Cancer has Poor Patient Outcomes
● Improved assessment of biomarkers can help
the patient
● Goal: Develop and implement new methods for
biomarker detection
8. Acknowledgments
Funding: Frank E. Duckwall Foundation, Saunders Foundation, Moffitt
Cancer Center
Koomen Lab
John Koomen, PhD
Melissa Martinez
Omar Chavez-Chiang, MD
Proteomics Core
Bin Fang, PhD
Lancia Darville, PhD
Victoria Izumi
Kiah Bowers
SPARK
Doug Cress, PhD
Evelyn Rivera-Miranda
Moffitt Cancer Center
Moffitt Foundation